Tg Therapeutics Inc Stock Price, News & Analysis

TG Therapeutics, Inc. (NASDAQ: TGTX) announced that CEO Michael S. Weiss will participate in a fireside chat at the Goldman Sachs 41^st Annual Healthcare Conference on June 11, 2020, at 4:40 PM ET. A live webcast will be available on the company's website. TG Therapeutics focuses on developing novel treatments for B-cell malignancies and autoimmune diseases, with therapies such as ublituximab and umbralisib in Phase 3 clinical development. The company is headquartered in New York City.

TG Therapeutics, Inc. (NASDAQ: TGTX) announced that its Executive Chairman and CEO, Michael S. Weiss, will participate in a fireside chat at the Jefferies 2020 Healthcare Conference on June 3, 2020, at 10:00 AM ET. This event will be virtual, and a live webcast can be accessed on the Company’s Investors & Media page. TG Therapeutics focuses on developing therapies for B-cell malignancies and autoimmune diseases, including the Phase 3 clinical development of ublituximab and umbralisib.

TG Therapeutics has announced favorable final results from its GENUINE Phase 3 study, which evaluated the impact of adding ublituximab to ibrutinib in patients with high-risk chronic lymphocytic leukemia (CLL). The combination significantly improved progression-free survival (PFS), overall response rate (ORR), and rates of undetectable minimal residual disease (uMRD) compared to ibrutinib alone. Specifically, ORR was 93% for the combination versus 78% for monotherapy. This study suggests a promising potential for ublituximab combined with ibrutinib in managing high-risk CLL.

On May 15, 2020, TG Therapeutics (NASDAQ: TGTX) announced that preclinical data for TG-1701, a selective BTK inhibitor, will be presented at the 2020 American Association for Cancer Research (AACR) annual meeting. The presentation, titled 'TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, does not inhibit anti-CD20-driven ADCC and ADCP in vitro,' will be available on demand starting June 22, 2020. TG Therapeutics is advancing multiple therapies for B-cell malignancies and autoimmune diseases and is currently in various clinical development phases.

TG Therapeutics (NASDAQ: TGTX) announced a $153 million public offering of 8,500,000 shares at $18.00 each, upsized from an initial estimate of 6 million shares. The offering is expected to close on May 19, 2020, pending standard conditions. Proceeds will support the development of ublituximab and umbralisib, possible acquisitions, and general corporate needs. The underwriters have a 30-day option for an additional 1,275,000 shares. Major financial institutions are managing the offering, which utilizes an effective shelf registration filed with the SEC.

TG Therapeutics (TGTX) announced plans to offer 6,000,000 shares of common stock in an underwritten public offering, subject to market conditions. The underwriters may purchase an additional 15% of the shares. Proceeds will fund the development of ublituximab and umbralisib, alongside potential acquisitions and general corporate needs. The offering is made under an effective shelf registration statement filed with the SEC. J.P. Morgan, Jefferies, Evercore, and Cantor Fitzgerald are managing the offering.

TG Therapeutics (NASDAQ: TGTX) announced data presentations scheduled for the ASCO and EHA annual meetings in May and June 2020. The company will present results from three combination trials, highlighting the GENUINE Phase 3 trial's final results that show a PFS benefit for ublituximab in high-risk CLL patients compared to ibrutinib alone. Additionally, long-term results from umbralisib and ibrutinib combinations will be discussed. The presentations emphasize the ongoing development of TGTX's novel therapies targeting B-cell malignancies.

TG Therapeutics, Inc. (NASDAQ: TGTX) reported a net loss of $51.1 million for Q1 2020, up from $35.2 million in Q1 2019. The company is buoyed by positive topline results from its UNITY-CLL Phase 3 trial and a strong cash position of approximately $154.3 million post-ATM facility utilization. Key milestones include the NDA submission for umbralisib in marginal zone lymphoma (MZL) and follicular lymphoma (FL) and the anticipated release of pivotal trial data in 2020. Despite increased R&D costs of $34 million, the company remains optimistic about future cash sufficiency through 2021.